Platform Adaptive trial of Novel antivirals for early treatment of COVID-19 in the community
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Molnupiravir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms PANORAMIC
- Sponsors Merck & Co
Most Recent Events
- 01 Jan 2025 Results (n=25783, data cut-off: 27 Apr 2022) assessing health outcomes from the longer term follow-up after 3 months and 6 months, presented in The Lancet Infectious Diseases
- 09 Apr 2024 Planned End Date changed from 30 Sep 2024 to 31 Mar 2025.
- 08 Mar 2024 Planned End Date changed from 31 Mar 2024 to 30 Sep 2024.